vs
AdvanSix Inc.（ASIX）与IONIS PHARMACEUTICALS INC（IONS）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是IONIS PHARMACEUTICALS INC的1.8倍（$359.9M vs $203.3M），AdvanSix Inc.净利率更高（-0.8% vs -112.8%，领先112.0%），AdvanSix Inc.同比增速更快（9.4% vs -10.3%），AdvanSix Inc.自由现金流更多（$36.1M vs $-159.0M），过去两年IONIS PHARMACEUTICALS INC的营收复合增速更高（30.4% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
ASIX vs IONS — 直观对比
营收规模更大
ASIX
是对方的1.8倍
$203.3M
营收增速更快
ASIX
高出19.6%
-10.3%
净利率更高
ASIX
高出112.0%
-112.8%
自由现金流更多
ASIX
多$195.1M
$-159.0M
两年增速更快
IONS
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $203.3M |
| 净利润 | $-2.8M | $-229.4M |
| 毛利率 | 7.6% | 96.1% |
| 营业利润率 | -0.7% | -105.5% |
| 净利率 | -0.8% | -112.8% |
| 营收同比 | 9.4% | -10.3% |
| 净利润同比 | -892.9% | -119.8% |
| 每股收益（稀释后） | $-0.11 | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXIONS
| Q4 25 | $359.9M | $203.3M | ||
| Q3 25 | $374.5M | $156.7M | ||
| Q2 25 | $410.0M | $452.0M | ||
| Q1 25 | $377.8M | $131.6M | ||
| Q4 24 | $329.1M | $226.6M | ||
| Q3 24 | $398.2M | $133.8M | ||
| Q2 24 | $453.5M | $225.3M | ||
| Q1 24 | $336.8M | $119.5M |
净利润ASIXIONS
| Q4 25 | $-2.8M | $-229.4M | ||
| Q3 25 | $-2.6M | $-128.6M | ||
| Q2 25 | $31.4M | $123.6M | ||
| Q1 25 | $23.3M | $-146.9M | ||
| Q4 24 | $352.0K | $-104.3M | ||
| Q3 24 | $22.3M | $-140.5M | ||
| Q2 24 | $38.9M | $-66.3M | ||
| Q1 24 | $-17.4M | $-142.8M |
毛利率ASIXIONS
| Q4 25 | 7.6% | 96.1% | ||
| Q3 25 | 6.8% | 98.5% | ||
| Q2 25 | 14.3% | 99.1% | ||
| Q1 25 | 14.2% | 98.9% | ||
| Q4 24 | 3.4% | 98.3% | ||
| Q3 24 | 14.4% | 99.2% | ||
| Q2 24 | 17.9% | 98.2% | ||
| Q1 24 | 0.9% | 98.2% |
营业利润率ASIXIONS
| Q4 25 | -0.7% | -105.5% | ||
| Q3 25 | -0.9% | -102.2% | ||
| Q2 25 | 7.7% | 30.9% | ||
| Q1 25 | 7.7% | -111.6% | ||
| Q4 24 | -3.9% | -48.9% | ||
| Q3 24 | 7.5% | -111.1% | ||
| Q2 24 | 11.5% | -29.3% | ||
| Q1 24 | -7.0% | -125.1% |
净利率ASIXIONS
| Q4 25 | -0.8% | -112.8% | ||
| Q3 25 | -0.7% | -82.1% | ||
| Q2 25 | 7.7% | 27.3% | ||
| Q1 25 | 6.2% | -111.6% | ||
| Q4 24 | 0.1% | -46.1% | ||
| Q3 24 | 5.6% | -105.0% | ||
| Q2 24 | 8.6% | -29.4% | ||
| Q1 24 | -5.2% | -119.5% |
每股收益（稀释后）ASIXIONS
| Q4 25 | $-0.11 | $-1.35 | ||
| Q3 25 | $-0.10 | $-0.80 | ||
| Q2 25 | $1.15 | $0.70 | ||
| Q1 25 | $0.86 | $-0.93 | ||
| Q4 24 | $0.02 | $-0.66 | ||
| Q3 24 | $0.82 | $-0.95 | ||
| Q2 24 | $1.43 | $-0.45 | ||
| Q1 24 | $-0.65 | $-0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $2.7B |
| 总债务越低越好 | — | $1.8B |
| 股东权益账面价值 | $815.2M | $489.1M |
| 总资产 | $1.7B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 3.71× |
8季度趋势，按日历期对齐
现金及短期投资ASIXIONS
| Q4 25 | $19.8M | $2.7B | ||
| Q3 25 | $23.7M | $2.2B | ||
| Q2 25 | $18.4M | $2.3B | ||
| Q1 25 | $8.3M | $2.1B | ||
| Q4 24 | $19.6M | $2.3B | ||
| Q3 24 | $17.3M | $2.5B | ||
| Q2 24 | $12.1M | $2.1B | ||
| Q1 24 | $20.6M | $2.2B |
总债务ASIXIONS
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASIXIONS
| Q4 25 | $815.2M | $489.1M | ||
| Q3 25 | $818.2M | $618.0M | ||
| Q2 25 | $823.7M | $631.7M | ||
| Q1 25 | $794.4M | $475.7M | ||
| Q4 24 | $774.6M | $588.4M | ||
| Q3 24 | $766.4M | $662.5M | ||
| Q2 24 | $746.6M | $263.7M | ||
| Q1 24 | $713.2M | $296.5M |
总资产ASIXIONS
| Q4 25 | $1.7B | $3.5B | ||
| Q3 25 | $1.7B | $3.0B | ||
| Q2 25 | $1.6B | $3.0B | ||
| Q1 25 | $1.6B | $2.8B | ||
| Q4 24 | $1.6B | $3.0B | ||
| Q3 24 | $1.5B | $3.1B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.5B | $2.8B |
负债/权益比ASIXIONS
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $-137.7M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $-159.0M |
| 自由现金流率自由现金流/营收 | 10.0% | -78.2% |
| 资本支出强度资本支出/营收 | 7.7% | 10.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $-320.0M |
8季度趋势，按日历期对齐
经营现金流ASIXIONS
| Q4 25 | $63.7M | $-137.7M | ||
| Q3 25 | $26.6M | $-131.4M | ||
| Q2 25 | $21.1M | $151.3M | ||
| Q1 25 | $11.4M | $-150.8M | ||
| Q4 24 | $64.2M | $-116.1M | ||
| Q3 24 | $57.3M | $-115.0M | ||
| Q2 24 | $50.2M | $-119.9M | ||
| Q1 24 | $-36.2M | $-149.9M |
自由现金流ASIXIONS
| Q4 25 | $36.1M | $-159.0M | ||
| Q3 25 | $66.0K | $-136.7M | ||
| Q2 25 | $-7.2M | $139.0M | ||
| Q1 25 | $-22.6M | $-163.4M | ||
| Q4 24 | $29.8M | $-141.6M | ||
| Q3 24 | $26.8M | $-124.0M | ||
| Q2 24 | $16.7M | $-126.1M | ||
| Q1 24 | $-71.6M | $-154.4M |
自由现金流率ASIXIONS
| Q4 25 | 10.0% | -78.2% | ||
| Q3 25 | 0.0% | -87.2% | ||
| Q2 25 | -1.7% | 30.8% | ||
| Q1 25 | -6.0% | -124.1% | ||
| Q4 24 | 9.1% | -62.5% | ||
| Q3 24 | 6.7% | -92.7% | ||
| Q2 24 | 3.7% | -56.0% | ||
| Q1 24 | -21.3% | -129.2% |
资本支出强度ASIXIONS
| Q4 25 | 7.7% | 10.5% | ||
| Q3 25 | 7.1% | 3.4% | ||
| Q2 25 | 6.9% | 2.7% | ||
| Q1 25 | 9.0% | 9.6% | ||
| Q4 24 | 10.4% | 11.3% | ||
| Q3 24 | 7.7% | 6.8% | ||
| Q2 24 | 7.4% | 2.8% | ||
| Q1 24 | 10.5% | 3.8% |
现金转化率ASIXIONS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | 1.22× | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
